Replies to post #26385 on $heff's $tation of $tocks & $olid DD

[jas2mel]

AEZS (1.30) agreed!! I bought my initial position this morning. I missed the last run.

[WarProfiteer]

AEZS Sold yesterday, and back in with ya today!

[EdF]

RE AZES, this may put some pressure on it:
http://finance.yahoo.com/news/terna-Zentaris-to-Raise-US15-prnews-1364341153.html?x=0&.v=1

Æterna Zentaris to Raise US$15 Million in Registered Direct Offering

Press Release Source: AETERNA ZENTARIS INC. On Thursday April 15, 2010, 8:40 pm EDT
QUEBEC CITY, April 15 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, announced today that it has received commitments from institutional investors to purchase US$15 million of securities in a registered direct offering. Under the terms of a Securities Purchase Agreement, the Company will sell to such institutional investors an aggregate of approximately 11.1 million common shares of its capital at a price of US$1.35 per share and issue warrants to acquire an aggregate of approximately 4.4 million common shares at an exercise price of US$1.50 per share.

The warrants to purchase additional common shares of Æterna Zentaris will be exercisable six months following their date of issuance and will expire on the fifth-year anniversary of the date on which they become exercisable. All of the securities were offered pursuant to an effective shelf registration statement filed in the United States. Proceeds from the transaction will be used for general corporate purposes, including clinical development, capital expenditures and for working capital. The offering is expected to be consummated no later than April 20, 2010, subject to customary closing conditions.

Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (NASDAQ:RODM - News), acted as the exclusive placement agent for the transaction.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any securities nor shall there be any sale of such securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. A shelf registration statement relating to the common shares and warrants issued in the offering (and the common shares issuable upon exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC") and has been declared effective. A prospectus supplement relating to the offering will be filed by the Company with the SEC and the Canadian securities regulatory authorities. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company or by contacting Æterna Zentaris Inc., 1405 du Parc-Technologique Boulevard, Quebec City, Canada G1P 4P5.

[$heff]

Alert...bought shares of CYCC at $2.38 in the Established Portfolio. They are presenting 6 abstracts at the AACR meeting that starts on Monday (Apr 17th-21st). These are solid forward-looking events to move this higher. This could move over $3.00 next week with the small float and O/S imo. DD posts to follow. $heff


6 abstracts at AACR for next week presentations.


>>> Cyclacel Pharmaceuticals Announces Multiple Abstracts Selected for Presentation at American Association for Cancer Research Annual Meeting

Translational Studies Highlight Unique Mechanism of Action and New Potential Clinical Applications for Sapacitabine and Seliciclib

April 1, 2010

BERKELEY HEIGHTS, N.J., April 1, 2010 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC - News) (Nasdaq:CYCCP - News) today announced that six abstracts highlighting translational and preclinical data for Cyclacel's cell cycle inhibitor drugs have been selected for presentation at the American Association of Cancer Research (AACR) Annual Meeting, being held from April 17-21, 2010, in Washington, DC.

The abstracts can be accessed through the AACR website, http://www.aacr.org/. Abstract titles are provided below. Please note that according to AACR policy, all data are embargoed until the time of the beginning of the presentation.

Sapacitabine:

"Understanding the pathways involved in the repair of CNDAC induced DNA damage"
Date/Time: Tuesday, Apr 20, 2010, 9:00 - 12:00 EDT
Abstract Number: 3502

Seliciclib and Second Generation CDK Inhibitors:

"Cyclin E amplification, a novel mechanism of resistance to trastuzumab
in HER2 amplified breast cancer"
Date/Time: Sunday, Apr 18, 2010, 14:25 -- 14:40 EDT
Abstract Number: 22


"Therapeutic potential of CDK inhibitors in MLL leukemias"
Date/Time: Tuesday, Apr 20, 2010, 14:00 -- 17:00 EDT
Abstract Number: 3886

"A novel derivative of the CDK inhibitor roscovitine that induces apoptosis in CLL and overcomes
stromal cell-mediated protection"
Date/Time: Tuesday, Apr 20, 2010, 14:00 -- 17:00 EDT
Abstract Number: 4431


CYC116:

"Tumor cell resistance mechanisms to aurora kinase inhibitors"
Date/Time: Sunday, Apr 18, 2010, 14:00 -- 17:00 EDT
Abstract Number: 633


Plk1 Inhibitors:

"Discovery, biological characterization and oral antitumor activity of polo-like kinase 1 (Plk1)
selective small molecule inhibitors"
Date/Time: Tuesday, Apr 20, 2010, 14:00 - 17:00 EDT
Abstract Number: 4435 <<<

[cccpmd666]

In AEZS at 1.28

GLTA

[barefootrunner]

AEZS (1.25) - Very good points and still very undervalued.

Capital raises are almost always viewed as negative, but this one was done intelligently and was well timed and was not overly dilutive. After the offering the o/s, including the unexercised warrants, will still be under 80mm and the float will be under 60mm.

At current levels, they are only trading 2x cash per share and last quarters earnings were positive (see below). Most big pharmas trade at much higher multiples to cash. To put it in perspective, AEZS has roughly the same cash per share as KERX! AEZS is on the left, KERX on the right:





Net earnings were $12.0 million, or $0.19 per basic and diluted share, for the quarter ended December 31, 2009, compared to a net loss of $14.5 million, or $0.27 per basic and diluted share,
for the same quarter in 2008. The significant increase in net earnings is largely attributable to the significant increase in license fee revenues, combined with lower comparative R&D expenses, as discussed above, partly offset by increased SG&A expenses and depreciation and amortization charges.

[$heff]

Alert...sold (stopped out) shares of AEZS at $1.10 in the Established Portfolio from my $1.27 entry. Stop-loss was executed! May re-enter if it moves under $1.00 and as we get closer to ASCO. Market is terrible today. $heff